(Q40430509)

20 September 2017

title

Cyclo-oxygenase-2 inhibitors : beneficial or detrimental for athletes with acute musculoskeletal injuries? (English)

1 reference

20 September 2017

Stuart J Warden

1

0 references

publication date

1 January 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

35

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

271-283

1 reference

https://scigraph.springernature.com/pub.10.2165/00007256-200535040-00001

20 September 2017

exact match

0 references

cites work

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00007256-200535040-00001

Adaptation to lengthening contractions is independent of voluntary muscle recruitment but relies on inflammation

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00007256-200535040-00001

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

21 January 2018

1 reference

12 December 2020

Basic science and clinical studies coincide: active treatment approach is needed after a sports injury

1 reference

12 December 2020

Indomethacin and aspirin: effect of nonsteroidal anti-inflammatory agents on the rate of fracture repair in the rat.

1 reference

12 December 2020

Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

1 reference

12 December 2020

Avoid cox inhibitors after skeletal surgery!

1 reference

12 December 2020

Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers

1 reference

12 December 2020

Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II.

1 reference

12 December 2020

Vioxx risk could signify trouble in class

1 reference

12 December 2020

Indomethacin and celecoxib improve tendon healing in rats

1 reference

12 December 2020

Renal pathology resulting from PGHS-2 gene ablation in DBA/B6 mice

1 reference

12 December 2020

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles

1 reference

12 December 2020

The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs

1 reference

12 December 2020

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

12 December 2020

Cyclooxygenase-2: regulation and relevance in inflammation

1 reference

12 December 2020

The tissue-specific, compensatory expression of cyclooxygenase-1 and -2 in transgenic mice

1 reference

12 December 2020

Anti-inflammatory treatment of muscular injuries in sport. An update of recent studies

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial

1 reference

12 December 2020

Effects of nonsteroidal anti-inflammatory drugs on bone formation and soft-tissue healing

1 reference

12 December 2020

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

1 reference

12 December 2020

Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.

1 reference

12 December 2020

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

1 reference

12 December 2020

Multiple controls in inflammation. Extracellular and intracellular phospholipase A2, inducible and constitutive cyclooxygenase, and inducible nitric oxide synthase

1 reference

12 December 2020

Do inhibitors of cyclooxygenase-2 impair bone healing?

1 reference

12 December 2020

Cyclo-oxygenase 2 function is essential for bone fracture healing

1 reference

12 December 2020

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

1 reference

12 December 2020

Coxibs and cardiovascular disease

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans

1 reference

12 December 2020

Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial

1 reference

12 December 2020

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

1 reference

12 December 2020

Chromosomal organization of the inducible and constitutive prostaglandin synthase/cyclooxygenase genes in mouse

1 reference

12 December 2020

Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats

1 reference

12 December 2020

Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs.

1 reference

12 December 2020

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

1 reference

12 December 2020

Anti-inflammatory therapy in sports injury. The role of nonsteroidal drugs and corticosteroid injection

1 reference

12 December 2020

Medical modifiers of sports injury. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) in sports soft-tissue injury

1 reference

12 December 2020

Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans.

1 reference

12 December 2020

Use of nonsteroidal anti-inflammatory drugs following exercise-induced muscle injury

1 reference

12 December 2020

Parecoxib impairs early tendon repair but improves later remodeling

1 reference

12 December 2020

Prostaglandin endoperoxide H synthases-1 and -2.

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor

1 reference

12 December 2020

Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs

1 reference

12 December 2020

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition

1 reference

12 December 2020

Biological mediators of acute inflammation

1 reference

12 December 2020

Regulated formation of eicosanoids

1 reference

12 December 2020

A cyclooxygenase-2 inhibitor impairs ligament healing in the rat.

1 reference

12 December 2020

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

12 December 2020

COX inhibitors and their effects on bone healing

1 reference

12 December 2020

The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion

1 reference

12 December 2020

Effect of COX-2-specific inhibition on fracture-healing in the rat femur

1 reference

12 December 2020

A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits. The Kapooka Ankle Sprain Study

1 reference

12 December 2020

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2

1 reference

12 December 2020

Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity

1 reference

12 December 2020

Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor.

1 reference

12 December 2020

Mechanotransduction in bone does not require a functional cyclooxygenase-2 (COX-2) gene

1 reference

12 December 2020

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

12 December 2020

NSAIDs and musculoskeletal treatment: what is the clinical evidence?

1 reference

12 December 2020

Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors

1 reference

12 December 2020

Role of prostacyclin in the cardiovascular response to thromboxane A2

1 reference

12 December 2020

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

1 reference

12 December 2020

Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair

1 reference

12 December 2020

Cyclooxygenase-2 inhibitor update.

1 reference

12 December 2020

The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: a concise review

1 reference

12 December 2020

Cyclooxygenase-2 inhibitor inhibits the fracture healing

1 reference

12 December 2020

Inhibitory effect on bone formation and calcification exerted by the anti-inflammatory drug ibuprofen. An experimental study on adult rat with fracture

1 reference

12 December 2020

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

12 December 2020

Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain.

1 reference

12 December 2020

Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

1 reference

12 December 2020

Prostacyclin: A Vascular Mediator

1 reference

12 December 2020

Inducible cyclooxygenase may have anti-inflammatory properties

1 reference

12 December 2020

10.2165/00007256-200535040-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

1020757940

0 references

1 reference